Three versus one year of adjuvant imatinib for high-risk   gastrointestinal stromal tumor (GIST): Survival analysis of a randomized   trial after 10 years of follow-up.

Titel:: Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.
Dokumenttyp:: Meeting Abstract
Autor(en):: Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hermes, Barbara; Schuette, Jochen; Cameron, Silke; Hohenberger, Peter; Jost, Philipp; Al-Batran, Salah-Eddin; Lindner, Lars H.; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt E.; Kallio, Raija S.; Jaakkola, Panu; Junnila, Jouni; Alvegard, Thor; Reichardt, Peter
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2020
Band / Volume:: 38 Suppl S
Heft / Issue:: 15
Print-ISSN:: 0732-183X
TUM Einrichtung:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Vorkommen: